Guideline on the Regulation of Therapeutic …

Guideline on the Regulation of Therapeutic Products in New Zealand Part 10: Requirements for information for prescribers and consumers Edition 7.0

  Guidelines, Product, Regulations, Therapeutic, Guideline on the regulation of therapeutic, Guideline on the regulation of therapeutic products in

Section 1: Legislation - Medsafe Home Page

Section 2: Overview of Regulation of Clinical Trials in New Zealand . Section summary Under Section 30 of the Medicines Act 1981, approval from the Director-General of

  Section, Clinical, Legislation, Section 1

Section 1: Legislation relating to the labelling - …

Part 5, Ed 1.6 Page 2 of 18 . Section 1: Legislation relating to the labelling of medicines and related products Section summary This section lists the legislation regulating the labelling of medicines and related products.

  Section, Relating, Legislation, Labelling, Section 1, Legislation relating to the labelling

NEW ZEALAND DATA SHEET - Medsafe

Treatment of recurrent, platinum-resistant disease: 10 mg/kg body weight given once every 2 weeks when administered in combination with one of …

  Sheet, Data, Zealand, New zealand data sheet

Madopar (levodopa) Data Sheet (DS) - Medsafe

MADOPAR 160202 1 Data Sheet MADOPAR® Levodopa + benserazide Capsules 62.5, 125 and 250; dispersible tablet 62.5; HBS modified-release capsule 125

  Levodopa, Dispersible

NEW ZEALAND DATA SHEET VERMOX® - …

NEW ZEALAND DATA SHEET VERMOX® Vermox® Page 2 of 7 For control of enterobiasis Adults and children 2-12 years: 1 Vermox tablet (100 mg) or 5 mL of suspension (100 mg) is given.

Clonazepam: oral drops (2.5 mg/ml); injection (1 mg).

2. you have severe and chronic lung disease 3. you have severe liver disease 4. you have an addiction to drugs or alcohol 5. the package is torn or shows signs of tampering

  Clonazepam

NEW ZEALAND DATA SHEET - Medsafe

NEW ZEALAND DATA SHEET 5 Hypnovel 170717 Medical history of alcohol or drug abuse Hypnovel should be avoided in patients with a medical history of alcohol or drug abuse.

  Drug

SCHEDULE OF FEES (effective from 1 July 2018)

Page 1 of 10. SCHEDULE OF FEES (effective from 1 July 2018) • All fees listed are GST inclusive. • More detailed descriptions of the type of application or change to which a fee applies can be

  Schedule, Effective, Fees, Schedule of fees

Nortriptyline (as hydrochloride) 10 mg and 25 mg Tablets

1 Nortriptyline NRIM 09052013 NEW ZEALAND DATA SHEET Nortriptyline NRIM . Nortriptyline (as hydrochloride) 10 mg and 25 mg Tablets . This product may not be interchangeable with similar products on the New Zealand market

Q8(R2) - ICH

The Pharmaceutical Development section should describe the knowledge that establishes that the type of dosage form selected and the formulation proposed are suitable for the intended use. This section should include sufficient information in each part to provide an understanding of the development of the drug product and its

  Form, Pharmaceutical, Section

Annex 1 WHO good practices for pharmaceutical quality ...

manufacture of a pharmaceutical dosage form and that, when so used, becomes an active ingredient of that pharmaceutical dosage form. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure and function of the body (1).

  Form, Pharmaceutical

Annex 5 Guidelines for stability testing of pharmaceutical ...

The stability of finished pharmaceutical products depends, on the one hand, on environmental factors such as ambient temperature, humidity and light, and, on the other, on product-related factors, e.g. the chemical and physical properties of the active substance and of pharmaceutical excipients, the dosage form and its composition, the

  Form, Pharmaceutical

Annex 9 Guidelines on packaging for pharmaceutical …

Guidelines on packaging for pharmaceutical products Introductory note 120 Glossary 121 1. Aspects of packaging 125 1.1 General considerations 125 1.2 Functions of packaging 127 1.2.1 Containment 127 1.2.2 Protection 127 1.3 Presentation and information 129 1.3.1 Labels 129 1.3.2 Repacking, relabelling and dispensing 130

  Guidelines, Product, Pharmaceutical, Packaging, Guidelines on packaging for pharmaceutical products, Guidelines on packaging for pharmaceutical

CRITERIA FOR DIAGNOSIS AND MANAGEMENT ... - Ministry …

Applications may be referred to the Medical Committee, established under Section 30 of the Poisons and Therapeutic Goods Act, for its advice. Subsequent applications should be made on Form 1 and a full progress report must be attached if requested. 6. REFERRAL TO GENERAL PRACTITIONERS

  Form, Section